Immune responses against persistent viral infections: Possible avenues for immunotherapeutic interventions

被引:26
作者
Fuse, Shinichiro [1 ]
Molloy, Michael J. [1 ]
Usherwood, Edward J. [1 ]
机构
[1] Dartmouth Med Sch, Dept Microbiol & Immunol, Lebanon, NH 03756 USA
关键词
immunotherapy; T cells; costimulation; cytokines; vaccination;
D O I
10.1615/CritRevImmunol.v28.i2.40
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Persistent viral infections present a significant threat to society, and treatment options for infected individuals are in urgent demand. During viral persistence, the balance between the virus and the host immune response is crucial. The immune system keeps the virus in check, and the virus counters by evading the immune response to avoid clearance, ultimately tipping the balance in favor of the virus and causing disease in many cases. Thus, efforts to tip the balance in favor of the host through immunotherapy holds promise for establishing control of viral replication. However, in most persistent viral infections, the continuous presence of the viral antigen renders virus-specific T cells to become dysfunctional. These differences can range from severe functional impairments in high-load persistent infections, to more subtle changes in infections with a lower virus burden. Recent work has shed light on immunoregulatory molecules or cytokines that affect viral persistence and/or T-cell function, and interventions that modulate these factors have led to effective viral control in experimental models. Exploitation of these experimental therapies may lead to treatments that would be of great clinical benefit to patients suffering from persistent virus infections, such as HIV, HBV, or HCV, or the herpesviruses CMV and EBV.
引用
收藏
页码:159 / 183
页数:25
相关论文
共 259 条
[1]   Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens [J].
Aandahl, EM ;
Michaëlsson, J ;
Moretto, WJ ;
Hecht, FA ;
Nixon, DF .
JOURNAL OF VIROLOGY, 2004, 78 (05) :2454-2459
[2]   Viral mechanisms of immune evasion [J].
Alcami, A ;
Koszinowski, UH .
TRENDS IN MICROBIOLOGY, 2000, 8 (09) :410-418
[3]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[4]   Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection [J].
Altfeld, M ;
Rosenberg, ES ;
Shankarappa, R ;
Mukherjee, JS ;
Hecht, FM ;
Eldridge, RL ;
Addo, MM ;
Poon, SH ;
Phillips, MN ;
Robbins, GK ;
Sax, PE ;
Boswell, S ;
Kahn, JO ;
Brander, C ;
Goulder, PJR ;
Levy, JA ;
Mullins, JI ;
Walker, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :169-180
[5]   Characterization of the CD4+T cell response Epstein-Barr virus during primary and persistent infection [J].
Amyes, E ;
Hatton, C ;
Montamat-Sicotte, D ;
Gudgeon, N ;
Rickinson, AB ;
McMichael, AJ ;
Callan, MFC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (06) :903-911
[6]   Early virus-associated bystander events affect the fitness of the CD8 T cell response to persistent virus infection [J].
Andrews, Nicolas P. ;
Pack, Christopher D. ;
Vezys, Vaiva ;
Barber, Glen N. ;
Lukacher, Aron E. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :7267-7275
[7]   Dynamics of T cell responses in HIV infection [J].
Appay, V ;
Papagno, L ;
Spina, CA ;
Hansasuta, P ;
King, A ;
Jones, L ;
Ogg, GS ;
Little, S ;
McMichael, AJ ;
Richman, DD ;
Rowland-Jones, SL .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3660-3666
[8]   Lessons from the study of T-cell differentiation in persistent human virus infection [J].
Appay, V ;
Rowland-Jones, SL .
SEMINARS IN IMMUNOLOGY, 2004, 16 (03) :205-212
[9]   Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections [J].
Appay, V ;
Dunbar, PR ;
Callan, M ;
Klenerman, P ;
Gillespie, GMA ;
Papagno, L ;
Ogg, GS ;
King, A ;
Lechner, F ;
Spina, CA ;
Little, S ;
Havlir, DV ;
Richman, DD ;
Gruener, N ;
Pape, G ;
Waters, A ;
Easterbrook, P ;
Salio, M ;
Cerundolo, V ;
McMichael, AJ ;
Rowland-Jones, SL .
NATURE MEDICINE, 2002, 8 (04) :379-385
[10]   Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus [J].
Arribillaga, L ;
Sarobe, P ;
Arina, A ;
Gorraiz, M ;
Borrás-Cuesta, F ;
Ruiz, J ;
Prieto, J ;
Chen, LP ;
Melero, I ;
Lasarte, JJ .
VACCINE, 2005, 23 (27) :3493-3499